DE69427705T2 - Bor-cluster enthaltende nukleoside und oligonukleoside - Google Patents

Bor-cluster enthaltende nukleoside und oligonukleoside

Info

Publication number
DE69427705T2
DE69427705T2 DE69427705T DE69427705T DE69427705T2 DE 69427705 T2 DE69427705 T2 DE 69427705T2 DE 69427705 T DE69427705 T DE 69427705T DE 69427705 T DE69427705 T DE 69427705T DE 69427705 T2 DE69427705 T2 DE 69427705T2
Authority
DE
Germany
Prior art keywords
oligonucleosides
bor
cluster containing
containing nucleosides
nucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69427705T
Other languages
English (en)
Other versions
DE69427705D1 (de
Inventor
F Schinazi
F Kattan
J Lesnikowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of DE69427705D1 publication Critical patent/DE69427705D1/de
Publication of DE69427705T2 publication Critical patent/DE69427705T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE69427705T 1993-12-02 1994-12-02 Bor-cluster enthaltende nukleoside und oligonukleoside Expired - Fee Related DE69427705T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/161,674 US6180766B1 (en) 1993-12-02 1993-12-02 Nucleosides and oligonucleotides containing boron clusters
PCT/US1994/013835 WO1995015333A1 (en) 1993-12-02 1994-12-02 Nucleosides and oligonucleotides containing boron clusters

Publications (2)

Publication Number Publication Date
DE69427705D1 DE69427705D1 (de) 2001-08-16
DE69427705T2 true DE69427705T2 (de) 2002-07-04

Family

ID=22582235

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69427705T Expired - Fee Related DE69427705T2 (de) 1993-12-02 1994-12-02 Bor-cluster enthaltende nukleoside und oligonukleoside
DE69435247T Expired - Fee Related DE69435247D1 (de) 1993-12-02 1994-12-02 Bor-cluster enthaltende Nukleoside und Oligonukleoside

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69435247T Expired - Fee Related DE69435247D1 (de) 1993-12-02 1994-12-02 Bor-cluster enthaltende Nukleoside und Oligonukleoside

Country Status (8)

Country Link
US (2) US6180766B1 (de)
EP (2) EP0731808B1 (de)
JP (2) JP4344959B2 (de)
AU (1) AU685892B2 (de)
CA (2) CA2617836A1 (de)
DE (2) DE69427705T2 (de)
ES (1) ES2161279T3 (de)
WO (1) WO1995015333A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180766B1 (en) 1993-12-02 2001-01-30 Raymond F. Schinazi Nucleosides and oligonucleotides containing boron clusters
US5599796A (en) * 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US5831046A (en) * 1996-08-05 1998-11-03 Prolinx, Incorporated Boronic acid-contaning nucleic acid monomers
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
US6083936A (en) * 1999-01-25 2000-07-04 Sri International Boron heterocycle steroid mimics and associated pharmaceutical compositions and methods of use
US6806363B1 (en) * 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
EP1239887A1 (de) 1999-10-15 2002-09-18 Mayo Foundation For Medical Education And Research Cobalamin-konjugate geeignet zur verwendung wie bilderzeugungs- oder therapeutische mitteln
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
AU2002243438A1 (en) * 2000-10-25 2002-07-24 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
WO2003026674A1 (en) * 2001-09-28 2003-04-03 Mayo Foundation For Medical Education And Research Coadministration of transport protein with conjugated cobalamin to deliver agents
US7662360B2 (en) * 2002-07-22 2010-02-16 Psimei Pharmaceuticals Plc Conjugates of N-hydroxypropymethacrylamide-methacrylate copolymer with nuclide activation agent and/or anti-cancer compounds
WO2004096824A2 (en) * 2003-05-02 2004-11-11 Centrum Mikrobiologii I Wirusologii Polskiej Akademii Nauk Nucleoside derivative, modified oligonucleotide, method for their synthesis and applications thereof
BRPI0610419A2 (pt) * 2005-05-17 2012-10-23 Cargill Inc lecitina granular, lisolecitina, processo para produzir lecitina granular, composição granular, processo para produzir uma composição de lecitina granular, produto, e, processos para produzir lisolecitina granular e para produzir uma composição de lisolecitina granular
SE528407C2 (sv) 2005-08-19 2006-11-07 Hammercap Ab Borföreningar användbara vid BNCT
WO2007098968A1 (en) * 2006-03-03 2007-09-07 Universität Bremen Triggered release of liposome contents
US20080050309A1 (en) * 2006-08-25 2008-02-28 Hadron Systems Compositions of pharmaceuticals for use in low energy neutron therapy
KR100884489B1 (ko) * 2007-02-21 2009-02-18 원광대학교산학협력단 1,3,5-트리아진-4-일-디카르보-클로소-도데카보란 유도체,이의 제조방법 및 이를 포함하는 약학적 조성물
US7572458B2 (en) 2007-06-11 2009-08-11 Ewha University-Industry Collaboration Foundation Boron compound-layered double hydroxide nanohybrid, method of preparing the boron compound-LDH nanohybrid, and pharmaceutical composition comprising the boron compound-LDH nanohybrid
DE102007038930B4 (de) * 2007-08-13 2013-12-05 Universität Leipzig Neue chemische Verbindung und deren Verwendung in der Medizin, insbesondere für die Verwendung in der Tumortherapie
PL387217A1 (pl) 2009-02-06 2010-08-16 Instytut Biologii Medycznej Polskiej Akademii Nauk Boranowe pochodne adenozyny
CN104151339B (zh) * 2013-05-17 2017-05-03 中国科学院近代物理研究所 含硼吖啶衍生物、其制备方法和应用
US20170216340A1 (en) * 2014-08-05 2017-08-03 Instytut Biologii Medycznej Polskiej Akademii Nauk A Nucleoside Derivative For Use As A Drug, Particularly For The Treatment Of Chronic Lymphocytic Leukemia
WO2017160741A1 (en) * 2016-03-13 2017-09-21 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
JP6360113B2 (ja) 2016-07-28 2018-07-18 ステラファーマ株式会社 ホウ素含有化合物
EP3544987A4 (de) 2016-11-23 2020-11-18 Wave Life Sciences Ltd. Zusammensetzungen und verfahren zur phosphoramidit- und oligonukleotidsynthese

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855493A (en) 1979-08-21 1989-08-08 The United States Of America, As Represented By The Secretary Of The Army Pharmacological active amine-carboxyboranes
US4516535A (en) 1982-06-22 1985-05-14 Nuclear Medicine, Inc. Methods for neutron-capture tumor therapy
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5328678A (en) 1987-11-04 1994-07-12 Vestar, Inc. Composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy
DE3803063A1 (de) 1988-01-29 1989-08-10 Schering Ag Thioharnstoffderivate, verfahren zu ihrer herstellung sowie ihre verwendung fuer die neutroneneinfangtherapie von malignen melanomen
US5066479A (en) 1988-05-31 1991-11-19 The Regents Of The Univ. Of California Metallacarborane chelates
US4959356A (en) 1989-05-26 1990-09-25 The United States Of America As Represented By The United States Department Of Energy Porphyrins for boron neutron capture therapy
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5171849A (en) 1991-04-19 1992-12-15 The Ohio State University Research Foundation 2' and 3' Carboranyl uridines and their diethyl ether adducts
JP3115386B2 (ja) 1991-12-12 2000-12-04 サントリー株式会社 含硼素ウリジン誘導体
US5405598A (en) 1992-02-24 1995-04-11 Schinazi; Raymond F. Sensitizing agents for use in boron neutron capture therapy
US5272250A (en) 1992-07-10 1993-12-21 Spielvogel Bernard F Boronated phosphoramidate compounds
US5466679A (en) * 1993-05-17 1995-11-14 The Ohio State University Research Foundation Carboranyl uridines and their use in boron neutron capture therapy
US5599796A (en) 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
US6180766B1 (en) 1993-12-02 2001-01-30 Raymond F. Schinazi Nucleosides and oligonucleotides containing boron clusters
AU6697994A (en) 1994-03-25 1995-10-17 Regents Of The University Of California, The Macromolecular structures for boron neutron-capture therapy

Also Published As

Publication number Publication date
EP1113020A2 (de) 2001-07-04
US20020160969A1 (en) 2002-10-31
CA2617836A1 (en) 1995-06-08
WO1995015333A1 (en) 1995-06-08
JP4344959B2 (ja) 2009-10-14
AU1299195A (en) 1995-06-19
EP0731808B1 (de) 2001-07-11
EP1113020A3 (de) 2003-04-16
EP1113020B1 (de) 2009-10-28
EP0731808A1 (de) 1996-09-18
CA2177952C (en) 2008-04-29
EP0731808A4 (de) 1997-04-02
US6583122B2 (en) 2003-06-24
US6180766B1 (en) 2001-01-30
JP2009067777A (ja) 2009-04-02
AU685892B2 (en) 1998-01-29
DE69427705D1 (de) 2001-08-16
ES2161279T3 (es) 2001-12-01
DE69435247D1 (de) 2009-12-10
CA2177952A1 (en) 1995-06-08
JPH10505318A (ja) 1998-05-26

Similar Documents

Publication Publication Date Title
DE69427705T2 (de) Bor-cluster enthaltende nukleoside und oligonukleoside
FI932521A0 (fi) Nytt endoglukanasenzym
DE69408359D1 (de) Substituierte Acylierungsmittel
DK0639932T3 (da) Ørehænger
DE59403737D1 (de) Drehkreuz
DE69406912T2 (de) Dispersion
DE9311354U1 (de) Sicherheitspuffer
FI934865A0 (fi) Dator foer fordon
KR950008000U (ko) 베개
KR950002883U (ko) 베개
KR950001897U (ko) 시료 채취기
DE69409358T2 (de) Elektrovisköses fluidum
KR950005530U (ko) 베개
KR950005528U (ko) 베개
KR950000322U (ko) 베개
DE9306115U1 (de) Schmuckstück
BR7200902U (pt) Aperfeicoamento em registro de esfera
KR940025411U (ko) 서예용 정간지
FI931273A (fi) Korvakoru
ITMI931648A1 (it) Azaciclo e azabiciclo ammidi
BR7300326U (pt) Disposicão em bombona
KR940025089U (ko) 완충구
FI1026U1 (fi) Provtagare
DE9318710U1 (de) Schlüsselanhänger
DE9301842U1 (de) Schlüsselanhänger

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication of lapse of patent is to be deleted
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee